1. Home
  2. REGN
  3. REGN News

Latest Regeneron Pharmaceuticals Inc. (REGN) News on October 6, 2024

Regeneron Pharmaceuticals, Inc. (REGN): A Buzzing AI Health Stock to Add to Your Portfolio
REGN

Insider Monkey

a day ago

Regeneron Pharmaceuticals, Inc. (REGN): A Buzzing AI Health Stock to Add to Your Portfolio

Should You Buy the Dip on This Top Growth Stock?
REGN

Motley Fool

a day ago

Should You Buy the Dip on This Top Growth Stock?

REGN

MT Newswires

2 days ago

Goldman Sachs Adjusts Price Target on Regeneron Pharmaceuticals to $1,294 From $1,292

REGN

MT Newswires

2 days ago

RBC Lifts Price Target on Regeneron Pharmaceuticals to $1,260 From $1,252, Keeps Outperform Rating

REGN

MT Newswires

3 days ago

Regeneron Pharmaceuticals Insider Sold Shares Worth $1,054,060, According to a Recent SEC Filing

Sanofi, Regeneron's Dupixent Gets FDA Approval for COPD
REGN

Zacks

6 days ago

Sanofi, Regeneron's Dupixent Gets FDA Approval for COPD

Regeneron, Sanofi announce Dupixent approval in China for patients with COPD
REGN

TipRanks

8 days ago

Regeneron, Sanofi announce Dupixent approval in China for patients with COPD

Jim Cramer on Regeneron Pharmaceuticals Inc. (REGN): ‘Leerink Analysts Downgraded Regeneron To A Market Perform Hold After A Negative Eylea 2mg Biosimilar Preliminary Injunction Ruling’
REGN

Insider Monkey

8 days ago

Jim Cramer on Regeneron Pharmaceuticals Inc. (REGN): ‘Leerink Analysts Downgraded Regeneron To A Market Perform Hold After A Negative Eylea 2mg Biosimilar Preliminary Injunction Ruling’

Regeneron-Sanofi Drug Wins FDA Approval To Treat COPD
REGN

Investopedia

9 days ago

Regeneron-Sanofi Drug Wins FDA Approval To Treat COPD

Regeneron Shares Head for Worst Month Since 2019 on Legal Ruling
REGN

Bloomberg

9 days ago

Regeneron Shares Head for Worst Month Since 2019 on Legal Ruling

FDA greenlights Regeneron’s Dupixent for the treatment of COPD
REGN

Pharmaceutical Technology

9 days ago

FDA greenlights Regeneron’s Dupixent for the treatment of COPD

Sanofi/Regeneron’s Dupixent set to dominate COPD biologics market following FDA approval
REGN

Pharmaceutical Technology

9 days ago

Sanofi/Regeneron’s Dupixent set to dominate COPD biologics market following FDA approval

REGN

MT Newswires

9 days ago

Regeneron, Sanofi Receive US FDA's Approval for Dupixent as Chronic Obstructive Pulmonary Disease Treatment

Regeneron, Sanofi Get FDA OK for Dupixent to Treat COPD
REGN

The Wall Street Journal

9 days ago

Regeneron, Sanofi Get FDA OK for Dupixent to Treat COPD

Regeneron And Sanofi Snag Their $6 Billion-Potential COPD Approval For Dupixent
REGN

Investor's Business Daily

9 days ago

Regeneron And Sanofi Snag Their $6 Billion-Potential COPD Approval For Dupixent

Dupixent® (dupilumab) Approved in the U.S. as the First-ever Biologic Medicine for Patients with COPD
REGN

GlobeNewswire

9 days ago

Dupixent® (dupilumab) Approved in the U.S. as the First-ever Biologic Medicine for Patients with COPD

REGN

MT Newswires

9 days ago

Sanofi, Regeneron Pharmaceuticals Receive Chinese Regulator's Approval for Dupixent as Chronic Obstructive Pulmonary Disease Treatment

Dupixent® (dupilumab) Approved in China as the First-ever Biologic Medicine for Patients with Chronic Obstructive Pulmonary Disease (COPD)
REGN

GlobeNewswire

9 days ago

Dupixent® (dupilumab) Approved in China as the First-ever Biologic Medicine for Patients with Chronic Obstructive Pulmonary Disease (COPD)

Regeneron to Report Third Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on October 31, 2024
REGN

GlobeNewswire

10 days ago

Regeneron to Report Third Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on October 31, 2024

REGN

Argus Research

10 days ago

Technical Assessment: Bullish in the Intermediate-Term

Amgen Stock Falls on Disappointing Drug Data
REGN

The Wall Street Journal

11 days ago

Amgen Stock Falls on Disappointing Drug Data

REGN

MT Newswires

12 days ago

US Equity Indexes Rise as Sliding Consumer Confidence Undermines Bowman's Call for Policy Caution

Regeneron Stock Down on Court Ruling for Amgen's Biosimilar of Eylea
REGN

Zacks

12 days ago

Regeneron Stock Down on Court Ruling for Amgen's Biosimilar of Eylea

REGN

Investing.com

12 days ago

Regeneron slump continues as analysts turn more cautious

HRMY vs. REGN: Which Stock Should Value Investors Buy Now?
REGN

Zacks

12 days ago

HRMY vs. REGN: Which Stock Should Value Investors Buy Now?

REGN

MT Newswires

12 days ago

RBC Capital Cuts Price Target on Regeneron Pharmaceuticals to $1,252 From $1,282, Outperform Rating Maintained

REGN

MT Newswires

12 days ago

Leerink Partners Downgrades Regeneron Pharmaceuticals to Market Perform From Outperform, Adjusts PT to $1,077 From $1,175

REGN

Morningstar Research

13 days ago

Analyst Report: Regeneron Pharmaceuticals, Inc.

REGN

MT Newswires

13 days ago

Regeneron Stock Slides After Court Rejects Injunction Against Eye Drug Biosimilar, Truist Says

Tesla Leads S&P 500 Index, While Biotech Giant Tumbles On Court Ruling
REGN

Investor's Business Daily

13 days ago

Tesla Leads S&P 500 Index, While Biotech Giant Tumbles On Court Ruling

Regeneron Dives As Amgen Tees Up Its Rival To Moneymaking Machine Eylea
REGN

Investor's Business Daily

13 days ago

Regeneron Dives As Amgen Tees Up Its Rival To Moneymaking Machine Eylea

Regeneron, SNY's Dupixent Get CHMP Recommendation for Label Expansion
REGN

Zacks

13 days ago

Regeneron, SNY's Dupixent Get CHMP Recommendation for Label Expansion

Sanofi's Sarclisa Gets FDA Nod for Expanded Use in Multiple Myeloma
REGN

Zacks

13 days ago

Sanofi's Sarclisa Gets FDA Nod for Expanded Use in Multiple Myeloma

REGN

MT Newswires

16 days ago

Regeneron, Sanofi Say Eosinophilic Esophagitis Drug Recommended for Children in EU

Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Eosinophilic Esophagitis (EoE) in Children as Young as 1 Year Old
REGN

GlobeNewswire

16 days ago

Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Eosinophilic Esophagitis (EoE) in Children as Young as 1 Year Old

The best biotech plays outside the GLP-1 weight-loss market
REGN

Yahoo Finance Video

17 days ago

The best biotech plays outside the GLP-1 weight-loss market

Jim Cramer Says Regeneron Pharmaceuticals Inc. (REGN)’s Oncology Portfolio is Beautiful
REGN

Insider Monkey

19 days ago

Jim Cramer Says Regeneron Pharmaceuticals Inc. (REGN)’s Oncology Portfolio is Beautiful

Regeneron, SNY Win FDA Approval for a Broader Dupixent Label
REGN

Zacks

20 days ago

Regeneron, SNY Win FDA Approval for a Broader Dupixent Label

ESMO 2024: Regeneron’s melanoma combo therapy benefit continues beyond two years
REGN

Clinical Trials Arena

20 days ago

ESMO 2024: Regeneron’s melanoma combo therapy benefit continues beyond two years

Regeneron’s Dupixent approved as first adolescent CRSwNP treatment
REGN

Pharmaceutical Technology

20 days ago

Regeneron’s Dupixent approved as first adolescent CRSwNP treatment

REGN

MT Newswires

23 days ago

Regeneron, Sanofi Get FDA Nod for Treatment of Chronic Rhinosinusitis With Nasal Polyps

Dupixent® (dupilumab) Approved in the U.S. as First and Only Treatment for Adolescents with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)
REGN

GlobeNewswire

23 days ago

Dupixent® (dupilumab) Approved in the U.S. as First and Only Treatment for Adolescents with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)

Pharma Stock Roundup: FDA Approves J&J's Tremfya for Ulcerative Colitis & More
REGN

Zacks

23 days ago

Pharma Stock Roundup: FDA Approves J&J's Tremfya for Ulcerative Colitis & More

Sanofi, Regeneron's Dupixent Meets Late-Stage Urticaria Study Goals
REGN

Zacks

25 days ago

Sanofi, Regeneron's Dupixent Meets Late-Stage Urticaria Study Goals

EYLEA HD® (aflibercept) Injection 8 mg Data at EURETINA Reinforce Long-term Durability, Sustained Fluid Control and Safety Profile
REGN

GlobeNewswire

25 days ago

EYLEA HD® (aflibercept) Injection 8 mg Data at EURETINA Reinforce Long-term Durability, Sustained Fluid Control and Safety Profile

Prediction: These 2 Companies Will Split Their Stocks by 2027
REGN

Motley Fool

25 days ago

Prediction: These 2 Companies Will Split Their Stocks by 2027

Dupixent succeeds in chronic hives study, giving Sanofi, Regeneron a chance to rebound
REGN

BioPharma Dive

25 days ago

Dupixent succeeds in chronic hives study, giving Sanofi, Regeneron a chance to rebound

REGN

MT Newswires

25 days ago

Regeneron, Sanofi's Dupixent Drug Meets Main Goal in 2 Late-Stage Trials

Dupixent® (dupilumab) Phase 3 Trial Confirms Significant Improvements in Itch and Hives for Patients with Chronic Spontaneous Urticaria (CSU)
REGN

GlobeNewswire

25 days ago

Dupixent® (dupilumab) Phase 3 Trial Confirms Significant Improvements in Itch and Hives for Patients with Chronic Spontaneous Urticaria (CSU)

Dupixent® (dupilumab) Is the First and Only Biologic to Achieve Significant Improvements in Disease Remission and Symptoms in Bullous Pemphigoid (BP) Positive Pivotal Trial
REGN

GlobeNewswire

25 days ago

Dupixent® (dupilumab) Is the First and Only Biologic to Achieve Significant Improvements in Disease Remission and Symptoms in Bullous Pemphigoid (BP) Positive Pivotal Trial

Libtayo® (cemiplimab) Demonstrates Durable Survival Benefit at Five Years in Advanced Non-small Cell Lung Cancer
REGN

GlobeNewswire

a month ago

Libtayo® (cemiplimab) Demonstrates Durable Survival Benefit at Five Years in Advanced Non-small Cell Lung Cancer

REGN

MT Newswires

a month ago

Regeneron Pharmaceuticals' Factor XI Antibodies to 'Generate More Attention,' RBC Says

REGN

MT Newswires

a month ago

Update: RBC Raises Price Target on Regeneron Pharmaceuticals to $1,282 From $1,250, Keeps Outperform Rating

Regeneron to Highlight Progress Across Its Differentiated Oncology Portfolio and Pipeline at WCLC and ESMO
REGN

GlobeNewswire

a month ago

Regeneron to Highlight Progress Across Its Differentiated Oncology Portfolio and Pipeline at WCLC and ESMO

REGN

MT Newswires

a month ago

RBC Raises Price Target on Regeneron Pharmaceuticals to $1,282 From $1,250, Keeps Outperform Rating

Regeneron Pharmaceuticals, Inc. (REGN): The Best Biotech Stock According to Hedge Funds?
REGN

Insider Monkey

a month ago

Regeneron Pharmaceuticals, Inc. (REGN): The Best Biotech Stock According to Hedge Funds?

Insider Sale: Director Arthur Ryan Sells Shares of Regeneron Pharmaceuticals Inc (REGN)
REGN

GuruFocus.com

a month ago

Insider Sale: Director Arthur Ryan Sells Shares of Regeneron Pharmaceuticals Inc (REGN)

REGN

MT Newswires

a month ago

Regeneron Pharmaceuticals Insider Sold Shares Worth $1,178,730, According to a Recent SEC Filing

Merck Starts Late-Stage Study on Recently Acquired Ophthalmology Drug
REGN

Zacks

a month ago

Merck Starts Late-Stage Study on Recently Acquired Ophthalmology Drug

REGN

MT Newswires

a month ago

RBC Capital Adjusts Price Target on Regeneron Pharmaceuticals to $1,250 From $1,240

Prediction: These 2 Cathie Wood Stocks Could Crush the Market Through 2030
REGN

Motley Fool

a month ago

Prediction: These 2 Cathie Wood Stocks Could Crush the Market Through 2030

REGN

MT Newswires

a month ago

Regeneron Pharmaceuticals Insider Sold Shares Worth $6,846,262, According to a Recent SEC Filing

Biotech Stock Roundup: REGN's Drug Approval, LXRX, RYTM Stocks Gain on Update & More
REGN

Zacks

a month ago

Biotech Stock Roundup: REGN's Drug Approval, LXRX, RYTM Stocks Gain on Update & More

Regeneron's Bispecific Antibody Obtains EC Nod for Lymphoma
REGN

Zacks

a month ago

Regeneron's Bispecific Antibody Obtains EC Nod for Lymphoma

REGN

Argus Research

a month ago

Technical Assessment: Bullish in the Intermediate-Term

HRMY or REGN: Which Is the Better Value Stock Right Now?
REGN

Zacks

a month ago

HRMY or REGN: Which Is the Better Value Stock Right Now?

Regeneron gains European approval for bispecific lymphoma drug
REGN

BioPharma Dive

a month ago

Regeneron gains European approval for bispecific lymphoma drug

REGN

MT Newswires

a month ago

Regeneron Pharmaceuticals Gets European Commission Approval for Ordspono

Ordspono™ (odronextamab) Approved in the European Union for the Treatment of Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma
REGN

GlobeNewswire

a month ago

Ordspono™ (odronextamab) Approved in the European Union for the Treatment of Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma

Latest Dupixent® (dupilumab) and Itepekimab Data at ERS Highlight Scientific Innovation and Leadership in Respiratory Diseases
REGN

GlobeNewswire

a month ago

Latest Dupixent® (dupilumab) and Itepekimab Data at ERS Highlight Scientific Innovation and Leadership in Respiratory Diseases

Alnylam (ALNY) Amvuttra & Givlaari Fuel Revenues Amid Competition
REGN

Zacks

a month ago

Alnylam (ALNY) Amvuttra & Givlaari Fuel Revenues Amid Competition

REGN

MT Newswires

a month ago

Piper Sandler Adjusts Price Target on Regeneron Pharmaceuticals to $1,242 From $1,166, Maintains Overweight Rating

REGN

Pharmaceutical Technology

a month ago

FDA declines to approve Regeneron’s linvoseltamab amid manufacturing issues

Regeneron confirms FDA won’t approve myeloma drug over manufacturing issues
REGN

BioPharma Dive

2 months ago

Regeneron confirms FDA won’t approve myeloma drug over manufacturing issues

Biotech Stock Roundup: CRL for REGN, GILD's Drug Approval, LQDA Down on News
REGN

Zacks

2 months ago

Biotech Stock Roundup: CRL for REGN, GILD's Drug Approval, LQDA Down on News

Regeneron (REGN) Gets CRL From FDA for Multiple Myeloma Drug
REGN

Zacks

2 months ago

Regeneron (REGN) Gets CRL From FDA for Multiple Myeloma Drug

Regeneron Provides Update on Biologics License Application for Linvoseltamab
REGN

GlobeNewswire

2 months ago

Regeneron Provides Update on Biologics License Application for Linvoseltamab

REGN

MT Newswires

2 months ago

Regeneron Pharmaceuticals Insider Sold Shares Worth $12,552,285, According to a Recent SEC Filing

REGN

MT Newswires

2 months ago

Regeneron Pharmaceuticals Insider Sold Shares Worth $884,520, According to a Recent SEC Filing

Regeneron Pharmaceuticals' (NASDAQ:REGN) five-year earnings growth trails the incredible shareholder returns
REGN

Simply Wall St.

2 months ago

Regeneron Pharmaceuticals' (NASDAQ:REGN) five-year earnings growth trails the incredible shareholder returns

REGN

MT Newswires

2 months ago

Regeneron Pharmaceuticals Insider Sold Shares Worth $7,337,505, According to a Recent SEC Filing

REGN

Morningstar Research

2 months ago

Analyst Report: Regeneron Pharmaceuticals, Inc.

FDA approves Sandoz’s Enzeevu as Eylea biosimilar saga continues
REGN

Pharmaceutical Technology

2 months ago

FDA approves Sandoz’s Enzeevu as Eylea biosimilar saga continues

Is There An Opportunity With Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) 47% Undervaluation?
REGN

Simply Wall St.

2 months ago

Is There An Opportunity With Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) 47% Undervaluation?

HRMY vs. REGN: Which Stock Is the Better Value Option?
REGN

Zacks

2 months ago

HRMY vs. REGN: Which Stock Is the Better Value Option?

What Makes Street Analysts Bullish on Regeneron Pharmaceuticals, Inc. (REGN) Now?
REGN

Insider Monkey

2 months ago

What Makes Street Analysts Bullish on Regeneron Pharmaceuticals, Inc. (REGN) Now?

REGN

MT Newswires

2 months ago

Argus Raises Price Target on Regeneron Pharmaceuticals to $1,175 From $1,170

REGN

Argus Research

2 months ago

Market Digest: COR, EA, J, PRU, REGN, WYNN, SMCI, SNAP, SHOP

REGN

Argus Research

2 months ago

Analyst Report: Regeneron Phars, Inc

Regeneron Announces Investor Conference Presentations and Oncology Investor Webcast
REGN

GlobeNewswire

2 months ago

Regeneron Announces Investor Conference Presentations and Oncology Investor Webcast

Nvidia, Meta, Netflix Profit Outlooks Sunny Despite Harsh Selling
REGN

Investor's Business Daily

2 months ago

Nvidia, Meta, Netflix Profit Outlooks Sunny Despite Harsh Selling

REGN

Argus Research

2 months ago

Technical Assessment: Bullish in the Intermediate-Term

REGN

Argus Research

2 months ago

Technical Assessment: Bullish in the Intermediate-Term

Insider Sale: Director Arthur Ryan Sells Shares of Regeneron Pharmaceuticals Inc (REGN)
REGN

GuruFocus.com

2 months ago

Insider Sale: Director Arthur Ryan Sells Shares of Regeneron Pharmaceuticals Inc (REGN)

Google's search monopoly, El-Erian talks the Fed: Market Domination
REGN

Yahoo Finance Video

2 months ago

Google's search monopoly, El-Erian talks the Fed: Market Domination

Investing in biotech outside of weight-loss drugs
REGN

Yahoo Finance Video

2 months ago

Investing in biotech outside of weight-loss drugs

Regeneron (REGN) Q2 Earnings Gain From Eylea HD, Dupixent
REGN

Zacks

2 months ago

Regeneron (REGN) Q2 Earnings Gain From Eylea HD, Dupixent

Regeneron Pharmaceuticals Insiders Sell US$26m Of Stock, Possibly Signalling Caution
REGN

Simply Wall St.

2 months ago

Regeneron Pharmaceuticals Insiders Sell US$26m Of Stock, Possibly Signalling Caution

Is Regeneron Pharmaceuticals Due for a Stock Split?
REGN

Motley Fool

2 months ago

Is Regeneron Pharmaceuticals Due for a Stock Split?

REGN

MT Newswires

2 months ago

Deutsche Bank Raises Price Target on Regeneron Pharmaceuticals to $990 From $870

Share on Social Networks: